QRx Pharma (United States)

Rationale and design of <scp>REDUCE‐IT</scp>: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Deepak L. Bhatt, Philippe Gabríel Steg, Eliot A. Brinton et al. · Clinical Cardiology · 2017 · 182 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin‐controlled LDL cholesterol

Gregory A. Nichols, Sephy Philip, Kristi Reynolds et al. · Diabetes Obesity and Metabolism · 2018 · 124 citations · Full text

Medicine, Cardiology, Clinical Cardiology +16

High Triglycerides Are Associated With Increased Cardiovascular Events, Medical Costs, and Resource Use: A Real‐World Administrative Claims Analysis of Statin‐Treated Patients With High Residual Cardiovascular Risk

Peter P. Tóth, Craig Granowitz, Michael Hüll et al. · Journal of the American Heart Association · 2018 · 119 citations · Full text

Medicine, Cardiology, Pharmacoeconomics +17

A Novel Selective Inhibitor JBI-589 Targets PAD4-Mediated Neutrophil Migration to Suppress Tumor Progression

Hui Deng, Cindy Lin, Laura Garcia-Gerique et al. · Cancer Research · 2022 · 78 citations · Full text

Medicine, Oncology, Pharmacology +17

Real-time on-line blend uniformity monitoring using near-infrared reflectance spectrometry: A noninvasive off-line calibration approach

Yusuf Sulub, Busolo Wabuyele, Paul Gargiulo et al. · Journal of Pharmaceutical and Biomedical Analysis · 2008 · 77 citations

Natural Sciences, Chemistry, Food Science +16